Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method
| Autor: | Linglin Feng, Jennifer Walker, Steven P. Schwendeman, Yan Wang, Avital Beig, Rose Ackermann, Justin K Y Hong, Tinghui Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Kinetics
Octreotide acetate Evaporation Pharmaceutical Science 02 engineering and technology Octreotide 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound Acetic acid 0302 clinical medicine Triethyl citrate Polylactic Acid-Polyglycolic Acid Copolymer Lactic Acid Particle Size 021001 nanoscience & nanotechnology Controlled release Microspheres PLGA Glucose chemistry Yield (chemistry) Delayed-Action Preparations Solvents 0210 nano-technology Polyglycolic Acid Nuclear chemistry |
| Zdroj: | Drug delivery and translational research. 12(3) |
| ISSN: | 2190-3948 |
| Popis: | Sandostatin long-acting release® (SLAR) is a long-acting injectable somatostatin analogue formulation composed of octreotide encapsulated in glucose-initiated poly(lactic-co-glycolic acid) (PLGA) microspheres. Despite the end of patent protection, SLAR remains resistant to generic competition likely due to complexity of production process, the uniqueness of the glucose star polymer, and the instability of octreotide in the formulation. Here, we describe development of glucose-PLGA-based composition-equivalent to SLAR formulations prepared by double emulsion-solvent evaporation method and the effect of variations in encapsulation variables on release kinetics and other formulation characteristics. The following encapsulation variables were adjusted at constant theoretical loading of 7.0% peptide: PLGA concentration, pH of inner water phase, and stirring rate. After final drying, the microspheres were examined with and without annealing at 50 °C under vacuum for 3 days. The loading and encapsulation efficiency (EE) of octreotide acetate, manufacturing yield, and in vitro drug release kinetics in PBStc (10 mM phosphate-buffered saline (PBS) with 1% triethyl citrate and 0.02% sodium azide at pH 7.4) were determined by UPLC. The in vitro release and acylation kinetics of octreotide for the solvent evaporation formulations prepared were similar to SLAR although the initial burst was slightly higher. Key formulation steps identified to maximize microsphere yield and minimize residual solvent and initial burst release included (a) addition of acetic acid to the peptide before preparation and (b) annealing the microspheres under vacuum after drying. Controlled release octreotide formulations prepared and investigated in this study could provide a better understanding of the effect of production variables on release performance and supply information useful for making progress in manufacturing of SLAR generic equivalents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink